B
Biomodal
Biotech & Life Sciences · Cambridge, United Kingdom · Founded 2012
Simultaneous genetic and epigenetic sequencing from single samples MoreLess
Originally founded as Cambridge Epigenetix in 2012 by Professor Sir Shankar Balasubramanian and Bobby Yerramilli-Rao, the company rebranded to Biomodal in April 2023. The company is headquartered in Cambridge, UK, and develops life sciences technology for researchers and clinical developers. The founders' journey began with research into epigenetic modifications, specifically 5-hydroxymethylcytosine, which led to a focus on creating new research tools.
Biomodal provides solutions that integrate into existing laboratory infrastructure to analyze both genetic and epigenetic data from a single, low-volume DNA sample in one workflow. The company's core technology, the duet multiomics solution, enables the sequencing of the '6-base genome', which includes the four standard DNA bases (A, C, G, T) plus two modified cytosines (5mC and 5hmC). This offers a more comprehensive view of the genome and its regulation, which is valuable for life scientists and clinical developers in fields like cancer research, neurodegenerative disease, aging, and liquid biopsies. The technology is hardware-agnostic, meaning it is compatible with existing sequencing machines, and includes a software pipeline for analysis.
The company's business model centers on selling these technology kits and software to research institutions and clinical development organizations. Biomodal has raised a total of approximately $164 million through multiple funding rounds, including a Series D round of $88 million in November 2021 led by Temasek. Other significant investors include GV (formerly Google Ventures), Sequoia Capital, and New Science Ventures.
Keywords: 6-base genome, genetic sequencing, epigenetic sequencing, multiomics solution, DNA methylation, single-base resolution, Cambridge Epigenetix, duet multiomics, 5-hydroxymethylcytosine, 5-methylcytosine, liquid biopsy, cancer research, neurodegenerative disease, cfDNA, omics, sequencing technology, research tools, clinical developers, biomarker discovery, single sample analysis, genomics, epigenomics, bioinformatics software
Company overview
Biomodal company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Cambridge, United Kingdom
- Employees
- 97
- Open positions
- None listed
- Dealroom signal
- 66.5
Valuation & funding
Biomodal funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Nov 2021 | $88M | $352M | Sequoia · Third Point Ventures · Ahren Innovation Capital · New Science Ventures | — |
| CONVERTIBLEOther financing | Nov 2020 | $11M | — | Undisclosed | — |
| SERIES COther financing | Sep 2018 | $30M | $120M | Ahren Innovation Capital | — |
| SERIES COther financing | Sep 2018 | — | — | Ahren Innovation Capital | — |
| SERIES COther financing | Apr 2018 | $30M | $120M | Sequoia · New Science Ventures · Ahren Innovation Capital · Syncona | — |
| SERIES BOther financing | Mar 2016 | New Science Ventures · University of Cambridge · Syncona · GV | ↗ | ||
| SERIES AOther financing | Oct 2014 | Cambridge Enterprise · Syncona · New Science Ventures | — | ||
| SPINOUTOther financing | Jan 2012 | University of Cambridge | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $377K | 0% | −$11M | -2970.5% |
| 2025 | $377K | 0% | −$11M | -2970.5% |
| 2024 | $377K | 0% | −$11M | -2970.5% |
| 2023 | $377K | 0% | −$11M | -2970.5% |
| 2022 | $377K | — | −$11M | -2970.5% |
Growth signals
Biomodal website traffic
Latest recorded traffic for Biomodal is 22K monthly website visits, down 18.5% over the last three months. Biomodal's team declined 13.4% over the past year.
Comparisons
Biomodal compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Biomodal's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Biomodal has talent and traffic
team presence
In the news
Latest news about Biomodal
Recent press, funding announcements, and product moves mentioning Biomodal — open to read from the original sources.
Market sentiment
What the market is saying about Biomodal
An AI-synthesized read of the highest-engagement posts about Biomodal on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biomodal’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.